Zobrazeno 1 - 10
of 41
pro vyhledávání: '"M. Schmitt-Haendle"'
Autor:
Klaus Krüger, Martin Feuchtenberger, Monika Ronneberger, H. Nuesslein, David Simon, Koray Tascilar, Axel J. Hueber, Juergen Rech, Hanns-Martin Lorenz, Michaela Reiser, Martin Fleck, Hans-Peter Tony, Rieke Alten, M. Schmitt-Haendle, Camille P. Figueiredo, Joerg Wendler, Wolfgang Ochs, Jayme Fogagnolo Cobra, F. Schuch, K. Manger, Georg Schett, Bernhard Manger, Matthias Englbrecht, Stefan Kleinert, Stephanie Finzel, Melanie Hagen, Joerg Henes, Arnd Kleyer
Publikováno v:
The Lancet Rheumatology. 3:e767-e777
Summary Background Owing to increasing remission rates, the management of patients with rheumatoid arthritis in sustained remission is of growing interest. The Rheumatoid Arthritis in Ongoing Remission (RETRO) study investigated tapering and withdraw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0dae4b1e241312843b533b69b20331b
https://doi.org/10.1016/s2665-9913(21)00220-4
https://doi.org/10.1016/s2665-9913(21)00220-4
Autor:
C Figuereido, H.-M. Lorenz, L. Valor, Jörg Wendler, M. Schmitt-Haendle, Martin Feuchtenberger, Jörg Henes, Jürgen Rech, Stefan Kleinert, H-P Tony, R. Alten, Martin Fleck, Axel J. Hueber, Stephanie Finzel, Bernhard Manger, Monika Ronneberger, Melanie Hagen, Judith Haschka, A. Kleyer, Michaela Reiser, Georg Schett, Klaus Krueger, Jayme Fogagnolo Cobra, F. Schuch, Wolfgang Ochs, Koray Tascilar, K. Manger
Publikováno v:
Annals of the Rheumatic Diseases. 80:194-195
Background:Due to better treatment strategies and higher remission rates the management of rheumatoid arthritis (RA) patients in sustained remission is of increasing interest (1). The Rheumatoid Arthritis in Ongoing Remission (RETRO) study investigat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11e0923fd2b90be45380a81c77825eb3
https://doi.org/10.1136/annrheumdis-2021-eular.2174
https://doi.org/10.1136/annrheumdis-2021-eular.2174
Autor:
C Figuereido, Jörg Henes, Marlene Stephan, Klaus Krueger, Hans-Peter Tony, Stefan Kleinert, Hanns-Martin Lorenz, Fabian Hartmann, Michaela Reiser, Stephanie Finzel, Karin Manger, Rieke Alten, M. Schmitt-Haendle, Wolfgang Ochs, Martin Feuchtenberger, Arnd Kleyer, Koray Tascilar, Georg Schett, Martin Fleck, Jürgen Rech, H. Nuesslein, Joerg Wendler, Jayme Fogagnolo Cobra, F. Schuch, Axel J. Hueber, Melanie Hagen, Monika Ronneberger, Judith Haschka, Bernhard Manger
Publikováno v:
Poster Presentations.
Background Several studies including our own RETRO study have shown that tapering or stopping disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients in sustained remission is feasible (1-3). However, tapering/stopping b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d787da89647d7e36151c20ed15212ff5
https://doi.org/10.1136/annrheumdis-2019-eular.3987
https://doi.org/10.1136/annrheumdis-2019-eular.3987
Autor:
K. Manger, Georg Schett, A. Kleyer, Jörg Wendler, Stephanie Finzel, Martin Feuchtenberger, Klaus Krueger, Jayme Fogagnolo Cobra, F. Schuch, Matthias Englbrecht, Axel J. Hueber, Bernhard Manger, Wolfgang Ochs, H. Nuesslein, Melanie Hagen, H.-M. Lorenz, Jörg Henes, M. Schmitt-Haendle, Jürgen Rech, H-P Tony, J. Erhard, Cmbf Figueiredo, Monika Ronneberger, Judith Haschka, Michaela Reiser, Stefan Kleinert, R. Alten, Martin Fleck
Publikováno v:
Rheumatoid arthritis – prognosis, predictors and outcome.
Background DAS28-ESR is the most widely used instrument to assess remission in rheumatoid arthritis (RA) patients. Nonetheless, substantial residual disease activity can be present in RA patients fullfilling DAS28-ESR remission. Therefore, more strin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65d6a9a5cc35fccb8e6b44b7be3caec0
https://doi.org/10.1136/annrheumdis-2018-eular.5521
https://doi.org/10.1136/annrheumdis-2018-eular.5521
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
H.-M. Lorenz, H. Nuesslein, Jörg Wendler, Wolfgang Ochs, Stefan Kleinert, H-P Tony, Martin Feuchtenberger, K. Manger, Jürgen Rech, Stephanie Finzel, Georg Schett, R. Alten, Michaela Reiser, Jörg Henes, Monika Ronneberger, Bernhard Manger, C Figuereido, Martin Fleck, J Fogagnolo Cobra, Matthias Englbrecht, Judith Haschka, Klaus Krueger, A. Kleyer, Axel J. Hueber, F. Schuch, Melanie Hagen, M. Schmitt-Haendle
Publikováno v:
Poster Presentations.
Background Tumor necrosis factor inhibitors (TNFi) are the most frequently used bDMARDs in RA patients. TNFi induces remission in a substantial numbers of patients. Once remission, particularly sustained remission is achieved the question arises whet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8e901118f78c4695ecea43cf439facb
https://doi.org/10.1136/annrheumdis-2017-eular.4787
https://doi.org/10.1136/annrheumdis-2017-eular.4787
Autor:
Michaela Reiser, C Figuereido, Martin Feuchtenberger, Jörg Wendler, Stefan Kleinert, Klaus Krueger, K. Manger, Georg Schett, A. Kleyer, Melanie Hagen, Monika Ronneberger, Jürgen Rech, Stephanie Finzel, Judith Haschka, Wolfgang Ochs, H.-M. Lorenz, F. Schuch, H. Nuesslein, Jörg Henes, Bernhard Manger, Matthias Englbrecht, H-P Tony, M. Schmitt-Haendle, J Fogagnolo Cobra, Axel J. Hueber, R. Alten, Martin Fleck
Publikováno v:
Oral Presentations.
Background Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying anti-rheumatic drugs (DMARD) about half of RA patients reach the diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fea2f5923942cc7c33745ee3daf075d
https://doi.org/10.1136/annrheumdis-2017-eular.2988
https://doi.org/10.1136/annrheumdis-2017-eular.2988
Autor:
Stephanie Finzel, K. Manger, Georg Schett, Rieke Alten, M. Schmitt-Haendle, Michaela Reiser, Joerg Henes, Camille P. Figueiredo, Wolfgang Ochs, Matthias Englbrecht, Bernhard Manger, Joerg Wendler, Hans-Peter Tony, Jayme Fogagnolo Cobra, F. Schuch, Arnd Kleyer, Martin Feuchtenberger, Klaus Krueger, Axel J. Hueber, Juergen Rech, Monika Ronneberger, Judith Haschka, Holger Bang, Stefan Kleinert, Martin Fleck, H. Nuesslein, Hanns-Martin Lorenz
Publikováno v:
Annals of the rheumatic diseases. 76(2)
ObjectiveTo perform a detailed analysis of the autoantibody response against post-translationally modified proteins in patients with rheumatoid arthritis (RA) in sustained remission and to explore whether its composition influences the risk for disea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb1f1009a66c3488f1776644ac9b9208
https://pubmed.ncbi.nlm.nih.gov/27627867
https://pubmed.ncbi.nlm.nih.gov/27627867
Autor:
Arnd Kleyer, Matthias Englbrecht, Hanns-Martin Lorenz, Wolfgang Ochs, Martin Feuchtenberger, Joerg Henes, Stefan Kleinert, Hans-Peter Tony, H. Nuesslein, Stephanie Finzel, K. Manger, Martin Fleck, Bernhard Manger, Georg Schett, Michaela Reiser, Monika Ronneberger, Juergen Rech, Judith Haschka, Axel J. Hueber, Klaus Krueger, Rieke Alten, M. Schmitt-Haendle, Camille P. Figueiredo, Joerg Wendler, Jayme Fogagnolo Cobra, F. Schuch
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveTo analyse the role of multibiomarker disease activity (MBDA) score in predicting disease relapses in patients with rheumatoid arthritis (RA) in sustained remission who tapered disease modifying antirheumatic drug (DMARD) therapy in RETRO, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6b8cc3cb90bf34fd0002b6a76cdbc54
https://opus4.kobv.de/opus4-fau/files/9684/Rech_prediction.pdf
https://opus4.kobv.de/opus4-fau/files/9684/Rech_prediction.pdf
Autor:
Hans-Peter Tony, Stefan Kleinert, Martin Fleck, M. Witt, Klaus Krueger, Mathias Grunke, Jörg Wendler, K. Manger, Hendrik Schulze-Koops, Wolfgang Ochs, Georg Schett, Bernhard Manger, Martin Feuchtenberger, Juergen Rech, Jochen Zwerina, Herbert Kellner, Kathrin St, F. Schuch, Matthias Englbrecht, Axel J. Hueber, M. Schmitt-Haendle
Publikováno v:
Rheumatology: Current Research.
Objectives: To investigate remission rates in rheumatoid arthritis patients exposed to tocilizumab treatment in real life clinical practice and to test whether concomitant conventional and previous biological disease modifying anti-rheumatic drugs tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13bd64d0a9cb243da58eb5bc52641fa9
https://doi.org/10.4172/2161-1149.1000157
https://doi.org/10.4172/2161-1149.1000157